Prognosis
China Approves Third Sinopharm Covid Vaccine for Clinical Trial
A healthcare worker prepares a dose of the Sinopharm Group Co. Covid-19 vaccine in Lima, Peru, earlier in February.
Photographer: Angela Ponce/BloombergThis article is for subscribers only.
China has approved the third Covid-19 vaccine from Sinopharm Group Co. to start clinical trials, the company said.
The green light to begin testing comes after two inactivated vaccines from Sinopharm were approved and widely used both at home and in developing countries.